## Byetta (exenatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:	
	., chart notes or lab data, to s	ely and legibly. Attach any additional documentation that is upport the authorization request). Information contained in	
		URGENT	
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:		-	
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID NU	MBER:		
FOLLOWING LINK: PRIMETHERAPEUTICS.COM  PATIENT'S AUTHORIZED REP	<sub>1/NOPP</sub> RESENTATIVE (IF APPLICABLE	CLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE	
PRESCRIBER INFORMATION			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF QUANTITY: THERAPY/REFILLS:	
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPI		" REVENUE DATE HIERALT INHIALLO.	
,	·		

Continued on next page.



## Byetta (exenatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Type II diabetes ☐ Other diagnosis:ICD	10	
Other diagnosis.	10	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Lab Values:		
Was the patient's most recent HbA1c	in the past 6 months or prior to startin	g the requested medication 7.0% or
greater? □ Yes □ No		
Documentation of HbA1c level requir	ed.	
-	filtration rate (GFR) less than or equal	to 45 mL/min/1.73 m2?  ☐ Yes ☐ No
Documentation of GFR required.		
Does the patient currently have a ser 30 mL/min/1.73 m2?  ☐ Yes ☐ No Documentation required.	um creatinine level exceeding 1.8 mg/d	L or an estimated GFR less than
Clinical information: Has the patient tried or is the patient	currently taking metformin?   Yes   N	0
Has treatment with metformin been	avoided due to lactic acidosis or elevate	ed liver enzymes? □ Yes □ No
Does the nationt have advanced liver	disease with at least one of the followi	ng? - Ves - No
If yes, please select:	disease with at least one of the following	ing: 🗆 res 🗀 NO
□ Ascites		
□ Cirrhosis		
☐ Hepatic encephalopathy		
☐ Portal hypertension		
Is the patient currently taking any of	the following medications? ☐ Yes ☐ No	
If <u>yes</u> , please select:		
☐ Janumet/Janumet XR (sitagliptin/n	netformin)	
□ Januvia (sitagliptin)		
☐ Jentadueto/Jentadueto XR (linaglip		
	ombiglyze XR (saxagliptin/metformin)	
□ Nesina (alogliptin)		
□ Onglyza (saxagliptin)		
□ Oseni (alogliptin/pioglitazone)		



## Byetta (exenatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

INIEINIBER 2 LAST NAINIE:	INTERVIBER'S FIRST NAME:
☐ Tradjenta (linagliptin)	
☐ Glyxambi(empagliflozin/linagliptin)	
☐ Seglujan(ertugliflozin/sitagliptin)	
☐ Qtern(dapagloflozin/saxagliptin)	
If the patient is taking any of the above medications discontinued?   Yes   No	s, will concomitant therapy with those medications be
Are there any other comments, diagnoses, sympton physician feels is important to this review?	ns, medications tried or failed, and/or any other information the
	all plans. This request may be denied unless all required
information is received.	
-	rue and accurate to the best of my knowledge. I understand that
	ees may perform a routine audit and request the medical
information necessary to verify the accuracy of the ir	nformation reported on this form.
Prescriber Signature or Electronic I.D. Verification: _	Date:
CONFIDENTIALITY NOTICE: The documents accompanying this tr	ransmission contain confidential health information that is legally privileged. If
	any disclosure, copying, distribution, or action taken in reliance on the contents
of these documents is strictly prohibited. If you have received the	is information in error, please notify the sender immediately (via return FAX)

**FAX THIS FORM TO: 800-424-7640** 

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program Attn: CP - 4201

P.O. Box 64811 St. Paul, MN 55164-0811

